Imbalances in serum proinflammatory cytokines and their soluble receptors: A putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy?

Clinical and Experimental Immunology

Volumn 114, Issue 3, 1998, Pages 468-476

  Rostoker, G ^a,b,c   Rymer, J C ^b   Bagnard, G ^b   Petit Phar, M ^b   Griuncelli, M ^a,b   Pilatte, Y ^b  

^a INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c Centre Hospitalier Prive Claude Galien   (France)

Author keywords

Henoch Schonlein syndrome; IgA nephropathy; Immunoglobulin therapy; TNF soluble receptors; Tumour necrosis factor alpha

Indexed keywords

IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANAPHYLACTOID PURPURA; ARTICLE; CLINICAL ARTICLE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOPATHOGENESIS; NEPHRITIS; PRIORITY JOURNAL; PROTEINURIA;

ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; CYTOKINES; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNIZATION, PASSIVE; INTERFERON TYPE II; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; MALE; PURPURA, SCHOENLEIN-HENOCH; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIALOGLYCOPROTEINS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031737511     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00745.x     Document Type: Article

References (54)

1. Galla J. IgA nephropathy. Kidney Int 1995; 47:377-87.
2. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med 1994; 120:476-84.
3. Rostoker G, Desvaux-Belghiti D, Pilatte Y et al. Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schönlein purpura: preliminary results of a prospective uncontrolled trial. Nephron 1995; 69:327-34.
4. Hammarströmin L, Lundkvist I, Petterson A, Edvard-Smith C. The use of IVIG in immunological disorders other than cytopenias. In: Yap PL, ed. Clinical applications of intravenous immunoglobulin therapy. Edinburgh: Churchill Livingstone, 1992:117-37.
5. Nydegger U. Hypothetic and established action mechanisms of therapy with immunoglobulin G. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:27-36.
6. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71:372-6.
7. Oliviera D. IgA related glomerulopathies. In: Oliviera D, ed. Immunological aspects of renal disease. Cambridge: University Press, 1992:87-113.
8. Montinaro V, Hevey K, Aventaggiato L et al. Extrarenal cytokines modulate the glomerular response to IgA immune complexes. Kidney Int 1992; 42:341-53.
9. Ortiz A, Gomez-Chiarri M, Alonso J et al. The potential role of inflammatory and fibrogenic cytokines in the glomerular diseases. J Lipid Med Cell Signalling 1994; 9:55-74.
10. Lee K, Rao V, Franklin W et al. IgA nephropathy, morphologic predictors of progressive renal disease. Hum Pathol 1982; 13:314-22.
11. Cockroft D, Gault M. Prediction of creatinine clearance from the serum creatinine. Nephron 1976; 16:31-41.
12. Whiteside T. Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol 1994; 14:327-39.
13. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985; 6:131-6.
14. Descamps-Latscha B, Herbelin A, Thu Nguyen A et al. Balance between IL1β, TNFα and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 1995; 154:882-92.
15. Herbelin A, Urena P, Thu Nguyen A et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39:954-60.
16. Dayer JM, Burger D. Interleukin 1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 1994; 5:563-71.
17. Dörge SE, Roux-Lombard P, Daher JM et al. Plasma levels of tumor necrosis factor and soluble TNF receptors in kidney transplant recipients. Transplantation 1994; 58:1000-8.
18. Imai H, Chen A, Wyatt R et al. Composition of IgA immune complexes precipitated with polyethylene glycol. A method for isolation and analysis of immune complexes. J Immunol Methods 1987; 103:239-15.
19. Rostoker G, Terzidis H, Petit-Phar M et al. Secretory IgA are elevated in both saliva and serum of patients with various types of primary glomerulonephritis. Clin Exp Immunol 1992; 90:305-11.
20. Reimer C, Philipps D, Aloisio C et al. Specificity and association constants of 33 monoclonal antibodies to human IgA epitopes. Immunol Letters 1989; 21:209-16.
21. Cederholm B, Wieslander J, Bygren Heinegard D. Circulating complexes containing IgA fibronectin in patients with primary IgA nephropathy. Proc Natl Acad Sci USA 1988; 85:4865-8.
22. Cavallo M, Pozzili P, Thorpe R. Cytokines and autoimmunity. Clin Exp Immunol 1994; 96:1-7.
23. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein absorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330:7-14.
24. Girardin E, Roux-Lombard P, Grau G et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992; 76:20-23.
25. Gherardi R, Belec L, Soubrier M et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996; 87:1458-65.
26. Bertani T, Abbate M, Zoja C et al. Tumor necrosis factor induces glomerular damage in rabbits. Am J Pathol 1989; 134:419-30.
27. Yanagisawa M, Imai H, Fukushima Y et al. Effects of tumor necrosis α and interleukin 1β on the proliferation of cultured glomerular epithelial cells. Virchows Arch 1994; 424:581-6.
28. Striker L, Peten E, Elliot S et al. Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest 1991; 64:446-56.
29. Tomosugi N, Cashman S, Pusey C et al. Modulation of antibody mediated glomerular injury in vivo by bacterial liposaccharide, tumor necrosis factor and IL1. J Immunol 1989; 142:3083-90.
30. Camussi G, Tetta C, Bussolino F et al. Effect of leukocyte stimulation on rabbit immune complex glomerulonephritis. Kidney Int 1990; 38:1047-55.
31. Hruby Z, Shirota K, Jothy S, Lowry R. Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury. Kidney Int 1991; 40:43-51.
32. Karkar A, Tam F, Steinkasserer A et al. Modulation of antibody-mediated glomerular injury in vivo by IL1-ra, soluble IL1 receptor and soluble TNF receptor. Kidney Int 1995; 48:1738-46.
33. Yoshioka K, Takemura T, Murakami K et al. In situ expression of cytokines in IgA nephritis. Kidney Int 1993; 44:825-33.
34. Matsumoto K. Increased release of tumor necrosis factor α by monocytes from patients with glomerulonephritis. Clin Nephrol 1993; 40:148-54.
35. Furukawa S, Matsubara T, Yone K et al. Kawasaki disease differs from anaphylactoid purpura and measles with regard, to tumour necrosis factor alpha and interleukin 6 in serum. Eur J Pediatr 1992; 151:44-47.
36. Tsai-Hung W, Shiu-Chuan W, Tung-Po H et al. Increased excretion of tumor necrosis factor alpha and interleukin 1 beta in urine from patients with IgA nephropathy and Schönlein-Henoch purpura. Nephron 1996; 74:79-88.
37. Yokohama H, Takaeda M, Wada T et al. Glomerular ICAM-1 expression related to circulating TNF-α in human glomerulonephritis. Nephron 1997; 76:425-33.
38. Achiron A, Margalit R, Hershkovitz R et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease: up regulation of T cell proliferation and down-regulation of tumor necrosis α secretion. J Clin Invest 1994; 93:6005.
39. Aukrust P, Froloand S, Liabakk N et al. Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43.
40. Chomarat P, Vannier E, Dechanet J et al. Balance of IL1 receptor antagonist/IL1β in rheumatoid synovium and its regulation by IL4 and IL10. J Immunol 1995; 154:1432-9.
41. Lan H, Nikolic-Paterson D, Zarama M et al. Suppression of experimental crescentic glomerulonephritis by the interleukin 1 receptor antagonist. Kidney Int 1993; 43:479-85.
42. Matsumoto K. Interleukin-1 production by monocytes from patients with glomerulonephritis after stimulation in vitro with soluble immune complexes. Clin Nephrol 1991; 36:267-73.
43. Suematsu S, Matsuda T, Aozasa K et al. IgG1 plasmocytosis in IL6 transgenic mice. Proc Natl Acad Sci USA 1989; 86:7547-51.
44. Horii Y, Muraguchi A, Iwano M et al. Involvement of IL6 in mesangial proliferative glomerulonephritis. J Immunol 1989; 143:3949-55.
45. Gordon C, Richards N, Howie A et al. Urinary IL6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol 1991; 86:145-9.
46. Nakamura T, Ebihara I, Takahashi T et al. Increased interleukin 6 mRNA expression by peripheral blood T cells from patients with IgA nephropathy. Autoimmunity 1993; 15:171-9.
47. Svenson M, Bagge Hansen M, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92:2533-9.
48. Yokoyama H, Takaeda M, Wada T et al. Intraglomerular expression of MHC class II and KI-67 antigens and serum γ interferon levels in IgA nephropatby. Nephron 1992; 62:169-75.
49. Chen A, Ding SL, Sheu LF et al. Experimental IgA nephropathy: enhanced deposition of glomerular IgA immune complex in proteinuric state. Lab Invest 1994; 70:639-47.
50. Jeannette C, Wieslander J, Tuttle et al. Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. Am J Kidney Dis 1991; 18:466-71.
51. Cosio F, Bakaletz A. The role of fibronectin on the clearance and tissue uptake of antigens and immune complexes in rats. J Clin Invest 1987; 80:1270-9.
52. Wahl S, Allen J, Hines H et al. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leucocyte adhesion and recruitment. J Clin Invest 1994; 94:655-62.
53. Wardle BN. Neutralizing inflammatory cytokines in nephritis. Nephron 1995; 69:223-7.
54. Ortiz A, Egido J. Is there a role for specific anti-TNF strategies in glomerular diseases? Nephrol Dial Transplant 1995; 10:309-11.